Loading companies…
A
Allogenetics
Germany · Biotech
Allogenetics is developing a one-time ex vivo gene therapy that modifies donor organs before transplantation, aiming to reduce immune rejection without suppressing the recipient’s immune system. Its lead ALG-115 program is advancing through preclinical and IND-enabling work for lung transplantation.
Engineer the graft before it is transplanted
Allogenetics' approach treats the donor organ rather than exposing the recipient to lifelong systemic immunosuppression. Its gene therapy is intended to reduce expression of HLA/MHC antigens that can trigger rejection, while preserving the recipient's ability to mount immune responses elsewhere.
The lead program ALG-115 is being prepared for IND-enabling studies, beginning with lung grafts. The company's pipeline also lists kidney and heart programs at preclinical stages and liver work in discovery. These are experimental therapies under development, not approved transplant treatments.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Pre-Series A | €3.8M | NBank Capital — LeadCARMA FUND — ParticipantLife Science Valley Wachstumsfonds — Participant |
Investors
NBank CapitalLed Pre-Series ACARMA FUNDJoined Pre-Series ALife Science Valley WachstumsfondsJoined Pre-Series ACoverage
Sep 9, 2026Allogenetics · Pre-Series ASimilar companies
AnaCardioAnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure.€62.5M · Series B
AventixAventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results.€1.2M · Pre-seed
ATAptadir TherapeuticsRNA therapeutics designed to restore expression of silenced genes€40M · Seed